TSX runs higher on rate cut expectations
Timothy T. Richards, a director at ClearPoint Neuro, Inc. (NASDAQ:CLPT), has sold 10,000 shares of the company’s common stock, according to a recent SEC filing. The transaction, which took place on June 10, 2025, was valued at approximately $132,800, with shares sold at a weighted average price of $13.28 each. The sale comes amid a remarkable year for CLPT, which has delivered a ~113% return over the past twelve months, according to InvestingPro data. The company, currently valued at $341 million, maintains a healthy balance sheet with liquid assets exceeding short-term obligations.
The sale was conducted to cover the tax liability related to the vesting of 21,903 shares under a restricted stock unit granted to Richards on May 16, 2024. Following this transaction, Richards retains ownership of 77,381 shares in the company. InvestingPro analysis indicates the stock is currently trading near its Fair Value, with 8 additional exclusive insights available to subscribers through the comprehensive Pro Research Report, which provides deep-dive analysis of CLPT among 1,400+ top US stocks.
In other recent news, ClearPoint Neuro Inc. reported its Q1 2025 revenue at $8.5 million, exceeding forecasts by 3.16% and marking an 11% increase from the previous year. This growth was largely attributed to a 70% surge in the Neurosurgery Navigation segment, despite a 63% decline in Capital Equipment and Software (ETR:SOWGn) revenue. The company is projecting annual revenue between $36 million and $41 million for 2025, with plans for 15-20 new site activations. ClearPoint Neuro is also pursuing GLP certification in the latter half of the year to support potential commercialization of new therapeutic products. The company recently secured funding from Overland Capital, providing financial flexibility with a new credit facility and equity investment. While operational cash burn increased by $2.3 million, ClearPoint Neuro remains focused on maintaining financial discipline. Analysts from Lake Street Capital Markets have noted the company’s progress and financial backing as positive developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.